Company / Operating Cash Flow
NEKTAR THERAPEUTICS Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$208.5M
FY2025
5-year range
-$412.7M / -$192.6M
FY2021-FY2025
Trend
-8.3%
vs FY2024
Sector context
#173 of 216
Health Care
What the data says
NEKTAR THERAPEUTICS's operating cash flow of -$209M is lower than 80% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 10 years, ranging from -$413M in FY2023 to $718M in FY2020.
Based on SEC 10-K filings.
-$209M in FY2025.
Improved from -$413M to -$209M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 216This company -$208.5M Sector average $659.0M
▼
-131.6% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 8.3% year-over-year.
- Ranks #173 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$208.5M | -8.3% |
| FY2024 | -$192.6M | +53.3% |
| FY2023 | -$412.7M | -35.7% |
| FY2022 | -$304.0M | +26.3% |
| FY2021 | -$412.7M | -157.5% |
| FY2020 | $718.2M | +993.1% |
| FY2019 | -$80.4M | +31.3% |
| FY2018 | -$117.0M | -45.5% |
| FY2017 | -$80.4M | +43.4% |
| FY2016 | -$142.0M | -94.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026